

# **Insurance Department**

JONATHAN T. PIKE *Insurance Commissioner* 

# Utah Drug Transparency Report April 2023

The *Utah Drug Transparency Report – April 2023* was prepared by Jeffrey E. Hawley, Ph.D. and Heather Sandberg, B.S. of the Health & Life Insurance Division for the Utah Insurance Commissioner pursuant to Utah Code § 31A-48-103. Publication date: May 22, 2023.

# For questions about this report contact:

Jeffrey E. Hawley, Ph.D.
Research Consultant
Health & Life Insurance Division
Utah Insurance Department
4315 S. 2700 West, Suite 2300
Taylorsville, Utah 84129
801-957-9284
jhawley@utah.gov

Shelley Wiseman Director Health & Life Insurance Division Utah Insurance Department 4315 S. 2700 West, Suite 2300 Taylorsville, Utah 84129 801-957-9296 swiseman@utah.gov

#### Overview

As required by Utah Code § 31A-48-103(1), drug manufacturers that are manufacturing a drug available for purchase by Utah residents with a wholesale acquisition cost (WAC) of at least \$100 or more for a 30-day supply are required to submit to the Utah Insurance Department (Department) the information described in § 31A-48-103(1)(b) and Utah Admin. Code R590-287 when an increase in the wholesale acquisition cost of the drug is 1) greater than 16 percent over the preceding two calendar years, or 2) greater than 10 percent over the preceding calendar year.

The information provided to the Department may not be released in a manner that: 1) would allow for the identification of an individual drug, therapeutic class of drugs, or manufacturer, or 2) is likely to compromise the financial, competitive, or proprietary nature of the information (see § 31A-48-103(4)).

The Department received 40 drug product reports during April 2023 that were in compliance with § 31A-48-103(1)(a). This report summarizes the following information received by drug manufacturers:

- 1) The effective date of the increase in the WAC price of the drug product,
- 2) The drug type (brand name drug or generic drug),
- 3) The manufacturer's aggregate company-wide research and development costs for the most recent year for which final audit data is available, and
- 4) A written description, suitable for public release, of the factors that led to the increase in the WAC price of the drug product and the significance of each factor.

The information has been de-identified to protect the identity of the individual drug, the therapeutic class of the drug, and the drug manufacturer as required by § 31A-48-103(4).

# List of Manufacturer Drug Product WAC Price Increase Reports by Effective Date

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/1/2022	Generic	\$0

#### Factors that led to the increase in the WAC price

WAC increases can be the result of changes in ingredient costs, changes in acquisition cost, manufacturing costs, sales cost, administrative expense, market conditions, supply shortages, etc.

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/1/2022	Generic	\$0

#### Factors that led to the increase in the WAC price

WAC increases can be the result of changes in ingredient costs, changes in acquisition cost, manufacturing costs, sales cost, administrative expense, market conditions, supply shortages, etc.

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/1/2022	Generic	\$0

#### Factors that led to the increase in the WAC price

WAC increases can be the result of changes in ingredient costs, changes in acquisition cost, manufacturing costs, sales cost, administrative expense, market conditions, supply shortages, etc.

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/1/2022	Generic	\$0

WAC increases can be the result of changes in ingredient costs, changes in acquisition cost, manufacturing costs, sales cost, administrative expense, market conditions, supply shortages, etc.

Effective Date	Drug Type	Company-Wide Research & Development Costs
2/1/2022	Generic	\$0

#### Factors that led to the increase in the WAC price

WAC increases can be the result of changes in ingredient costs, changes in acquisition cost, manufacturing costs, sales cost, administrative expense, market conditions, supply shortages, etc.

Effective Date	Drug Type	Company-Wide Research & Development Costs
2/1/2022	Generic	\$0

#### Factors that led to the increase in the WAC price

WAC increases can be the result of changes in ingredient costs, changes in acquisition cost, manufacturing costs, sales cost, administrative expense, market conditions, supply shortages, etc.

Effective Date	Drug Type	Company-Wide Research & Development Costs
2/1/2022	Generic	\$0

# Factors that led to the increase in the WAC price

WAC increases can be the result of changes in ingredient costs, changes in acquisition cost, manufacturing costs, sales cost, administrative expense, market conditions, supply shortages, etc.

Effective Date	Drug Type	Company-Wide Research & Development Costs
4/1/2022	Generic	\$0

WAC increases can be the result of changes in ingredient costs, changes in acquisition cost, manufacturing costs, sales cost, administrative expense, market conditions, supply shortages, etc.

Effective Date	Drug Type	Company-Wide Research & Development Costs
4/1/2022	Generic	\$0

#### Factors that led to the increase in the WAC price

WAC increases can be the result of changes in ingredient costs, changes in acquisition cost, manufacturing costs, sales cost, administrative expense, market conditions, supply shortages, etc.

Effective Date	Drug Type	Company-Wide Research & Development Costs
4/1/2022	Generic	\$0

#### Factors that led to the increase in the WAC price

WAC increases can be the result of changes in ingredient costs, changes in acquisition cost, manufacturing costs, sales cost, administrative expense, market conditions, supply shortages, etc.

Effective Date	Drug Type	Company-Wide Research & Development Costs
8/30/2022	Generic	\$0

# Factors that led to the increase in the WAC price

WAC increases can be the result of changes in ingredient costs, changes in acquisition cost, manufacturing costs, sales cost, administrative expense, market conditions, supply shortages, etc.

	Drug Type	Company-Wide Research & Development Costs
12/20/2022	Brand	\$743,213
Factors that led	to the increase	in the WAC price
Increase is bas inflation, and s		ty of factors including those related to the cost of production, increase materials, general es
Effective Date	Drug Type	Company-Wide Research & Development Costs
12/24/2022	Generic	\$195,688,000
Factors that led	to the increase	in the WAC price
		d cost to manufacture plus additional controlled substance customer fees
Effective Date	Drug Type	Company-Wide Research & Development Costs
<i>Effective Date</i> 12/24/2022	Drug Type Generic	Company-Wide Research & Development Costs \$195,688,000
12/24/2022	Generic	
12/24/2022  Factors that led	Generic  to the increase	\$195,688,000
12/24/2022  Factors that led	Generic  to the increase	\$195,688,000  in the WAC price
12/24/2022  Factors that led Increases in ra	Generic  to the increase w material and	\$195,688,000  in the WAC price d cost to manufacture plus additional controlled substance customer fees
12/24/2022  Factors that led Increases in ra  Effective Date 12/24/2022	Generic  to the increase w material and  Drug Type Generic	\$195,688,000  in the WAC price d cost to manufacture plus additional controlled substance customer fees  Company-Wide Research & Development Costs

Effective Date	Drug Type	Company-Wide Research & Development Costs	
12/24/2022	Generic	\$195,688,000	
Factors that led	to the increase	in the WAC price	
Increases in ra	w material an	d cost to manufacture plus additional controlled substance customer fees	
Effective Date	Drug Type	Company-Wide Research & Development Costs	
12/24/2022	Generic	\$195,688,000	
		in the WAC price d cost to manufacture plus additional controlled substance customer fees	
Increases in ra  Effective Date	w material and  Drug Type	d cost to manufacture plus additional controlled substance customer fees  Company-Wide Research & Development Costs	
Increases in ra  Effective Date	w material an	d cost to manufacture plus additional controlled substance customer fees	
Increases in ra  Effective Date  12/24/2022	w material and  Drug Type Generic	d cost to manufacture plus additional controlled substance customer fees  Company-Wide Research & Development Costs	
Increases in ra  Effective Date  12/24/2022  Factors that led	w material and  Drug Type Generic  to the increase	d cost to manufacture plus additional controlled substance customer fees  Company-Wide Research & Development Costs \$195,688,000	
Increases in ra  Effective Date 12/24/2022  Factors that led	w material and  Drug Type Generic  to the increase	d cost to manufacture plus additional controlled substance customer fees  **Company-Wide Research & Development Costs** \$195,688,000  **in the WAC price**	

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/4/2023	Brand	\$4,819,000,000

<Manufacturer> understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/4/2023	Brand	\$4,819,000,000

#### Factors that led to the increase in the WAC price

<Manufacturer> understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/4/2023	Brand	\$4,819,000,000

# Factors that led to the increase in the WAC price

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/4/2023	Brand	\$4,819,000,000

<Manufacturer> understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/4/2023	Brand Brand	\$4,819,000,000

#### Factors that led to the increase in the WAC price

<Manufacturer> understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/4/2023	Brand	\$4,819,000,000

# Factors that led to the increase in the WAC price

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/4/2023	Brand	\$4,819,000,000

<Manufacturer> understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/4/2023	Brand Brand	\$4,819,000,000

#### Factors that led to the increase in the WAC price

<Manufacturer> understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employing flexible pricing approaches to ensure patient access

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/4/2023	Brand	\$4,819,000,000

# Factors that led to the increase in the WAC price

	Drug Type	Company-Wide Research & Development Costs
1/4/2023	Brand	\$3,170,000,000
Factors that led	to the increase	in the WAC price
		continued investment in innovation, post-marketing regulatory commitments, ongoing conditions and dynamics
Effective Date	Drug Type	Company-Wide Research & Development Costs
1/4/2023	Brand	\$3,170,000,000
Factors that led	to the increase	in the WAC price
		continued investment in innovation, post-marketing regulatory commitments, ongoing conditions and dynamics
Effective Date	Drug Type	Company-Wide Research & Development Costs
	Drug Type Brand	Company-Wide Research & Development Costs \$3,170,000,000
Effective Date 1/4/2023 Factors that led	Brand	
1/4/2023  Factors that led Increases in ra	Brand  to the increase te of inflation,	\$3,170,000,000
1/4/2023  Factors that led Increases in rapharmacovigila	Brand  to the increase te of inflation,	\$3,170,000,000  in the WAC price continued investment in innovation, post-marketing regulatory commitments, ongoing
1/4/2023  Factors that led Increases in ra	Brand  to the increase te of inflation, ance, market o	\$3,170,000,000  in the WAC price continued investment in innovation, post-marketing regulatory commitments, ongoing conditions and dynamics

pharmacovigilance, market conditions and dynamics

Effective Date	Drug Type	Company-Wide Research & Development Costs
1/4/2023	Brand	\$3,170,000,000
Factors that led	to the increase	in the WAC price
		continued investment in innovation, post-marketing regulatory commitments, ongoing
oharmacovigila	ance, market c	conditions and dynamics
Effective Date	Drug Type	Company-Wide Research & Development Costs
×.v	Brand	\$3,170,000,000
1/4/2023	Diana	ψο, 17 ο,000,000
		in the WAC price
Factors that led Increases in ra	to the increase te of inflation,	in the WAC price continued investment in innovation, post-marketing regulatory commitments, ongoing
Factors that led Increases in ra	to the increase te of inflation,	in the WAC price
Factors that led Increases in ra	to the increase te of inflation,	in the WAC price continued investment in innovation, post-marketing regulatory commitments, ongoing

pharmacovigilance, market conditions and dynamics

Effective Date	Drug Type	Company-Wide Research & Development Costs
3/15/2023	Generic	\$23,954,892

Effective Date	Drug Type	Company-Wide Research & Development Costs
3/15/2023	Generic	\$23,954,892

# Factors that led to the increase in the WAC price

Effective Date	Drug Type	Company-Wide Research & Development Costs
3/15/2023	Generic	\$23,954,892

# Factors that led to the increase in the WAC price

The change in WAC price reflects the increased cost to supply efficiently to patients due to supply chain constraints, increased cost of storage, additional overhead, and marketing costs. Manufacturer> and many drug manufacturers have seen increase in the cost of doing business due to the supply chain disruptions of COVID, shipping costs, high inflation rates impacting the cost of goods, the cost of hiring and keeping key resources, and other factors has lead to the increase in prices in order to continue to provide life changing therapy to patients.

Effective Date	Drug Type	Company-Wide Research & Development Costs
3/30/2023	Brand	\$1,344,361,000

<Manufacturer> considers the clinical benefit this medicine brings to patients in disease areas with a high unmet need, the size of the patient population we hope to treat, the innovation of <drug product> and the ability of healthcare systems to provide broad access for patients.

Effective Date	Drug Type	Company-Wide Research & Development Costs
3/30/2023	Brand	\$1,344,361,000

# Factors that led to the increase in the WAC price

<Manufacturer> considers the clinical benefit this medicine brings to patients in disease areas with a high unmet need, the size of the patient population we hope to treat, the innovation of <drug product> and the ability of healthcare systems to provide broad access for patients.